Colleen Kusy's Stock Ratings

Baird Analyst

Colleen Kusy is an analyst at Baird. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/07/2024

Overall Average Return

-14.5%

Smart Score

34.6%

Overall Average Return Percentile

16th

Number of Ratings

37
Buy NowGet Alert
07/01/2024CHRSBuy Now
Coherus BioSciences
$1.29520.16%$9 → $8MaintainsOutperformGet Alert
06/28/2024APLSBuy Now
Apellis Pharmaceuticals
$37.01170.2%$100 → $100MaintainsOutperformGet Alert
06/11/2024OCSBuy Now
Oculis Holding
$12.36199.35%$35 → $37MaintainsOutperformGet Alert
06/11/2024ELVNBuy Now
Enliven Therapeutics
$22.8040.35% → $32Initiates → OutperformGet Alert
05/02/2024SYREBuy Now
Spyre Therapeutics
$26.5588.32% → $50Initiates → OutperformGet Alert
03/19/2024OCSBuy Now
Oculis Holding
$12.36183.17%$64 → $35MaintainsOutperformGet Alert
03/12/2024ORICBuy Now
ORIC Pharmaceuticals
$8.50194.12%$27 → $25ReiteratesOutperform → OutperformGet Alert
02/29/2024MRSNBuy Now
Mersana Therapeutics
$1.88165.96%$1 → $5MaintainsNeutralGet Alert
02/23/2024NUVLBuy Now
Nuvalent
$72.3345.17% → $105Initiates → OutperformGet Alert
02/06/2024APLSBuy Now
Apellis Pharmaceuticals
$37.01118.86% → $81ReiteratesOutperform → OutperformGet Alert
01/23/2024CHRSBuy Now
Coherus BioSciences
$1.29597.67%$11 → $9MaintainsOutperformGet Alert
01/17/2024APLSBuy Now
Apellis Pharmaceuticals
$37.01118.86%$71 → $81MaintainsOutperformGet Alert
11/17/2023CHRSBuy Now
Coherus BioSciences
$1.29752.71% → $11Initiates → OutperformGet Alert
09/14/2023OCULBuy Now
Ocular Therapeutix
$6.67169.87% → $18ReiteratesOutperform → OutperformGet Alert
08/01/2023APLSBuy Now
Apellis Pharmaceuticals
$37.0189.14%$115 → $70MaintainsOutperformGet Alert
07/28/2023MRSNBuy Now
Mersana Therapeutics
$1.88-46.81%$7 → $1DowngradeOutperform → NeutralGet Alert
06/20/2023SURFBuy Now
Surface Oncology
DowngradeOutperform → NeutralGet Alert
06/13/2023OCULBuy Now
Ocular Therapeutix
$6.6779.91%$10 → $12MaintainsOutperformGet Alert
06/08/2023OCSBuy Now
Oculis Holding
$12.36369.26% → $58Initiates → OutperformGet Alert
06/06/2023AGENBuy Now
Agenus
$15.56-48.59% → $160Initiates → OutperformGet Alert
05/04/2023SURFBuy Now
Surface Oncology
→ $6MaintainsOutperformGet Alert
05/04/2023ISEEBuy Now
IVERIC bio
→ $40DowngradeOutperform → NeutralGet Alert
04/21/2023OCULBuy Now
Ocular Therapeutix
$6.67169.87% → $18Initiates → OutperformGet Alert
02/21/2023APLSBuy Now
Apellis Pharmaceuticals
$37.01183.71%$90 → $105MaintainsOutperformGet Alert
11/15/2022HARPBuy Now
Harpoon Therapeutics
DowngradeOutperform → NeutralGet Alert
11/03/2022SURFBuy Now
Surface Oncology
$11 → $6MaintainsOutperformGet Alert
10/19/2022AVEOBuy Now
AVEO Pharmaceuticals
$17 → $15DowngradeOutperform → NeutralGet Alert
09/07/2022ISEEBuy Now
IVERIC bio
$27 → $34MaintainsOutperformGet Alert
08/09/2022MRSNBuy Now
Mersana Therapeutics
$1.88963.83%$18 → $20MaintainsOutperformGet Alert
08/05/2022KPTIBuy Now
Karyopharm Therapeutics
$0.791671.93%$17 → $14MaintainsOutperformGet Alert
08/03/2022SURFBuy Now
Surface Oncology
$11 → $11MaintainsOutperformGet Alert
05/09/2022SURFBuy Now
Surface Oncology
$11 → $11MaintainsOutperformGet Alert
04/13/2022SURFBuy Now
Surface Oncology
→ $11MaintainsOutperformGet Alert
04/07/2022IOVABuy Now
Iovance Biotherapeutics
$7.32364.48%$30 → $34MaintainsOutperformGet Alert
03/03/2022ISEEBuy Now
IVERIC bio
→ $27Initiates → OutperformGet Alert
02/25/2022IOVABuy Now
Iovance Biotherapeutics
$7.32309.84%$35 → $30MaintainsOutperformGet Alert
11/02/2021SABSBuy Now
SAB Biotherapeutics
$2.71748.71% → $230Initiates → OutperformGet Alert